Fundz
Following Drug Farm?

Get the free weekly contract digest

The latest new contracts, like Drug Farm’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Drug Farm Signs Agreement with National Institutes of Health (NIH) to Develop Precision Targeted Treatment for ROSAH Syndrome

Dec 19, 2024•over 1 year ago

Contract Type

agreement

Shanghai

Description

Drug Farm, a clinical-stage biopharmaceutical company, announced the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to develop a precision targeted drug, DF-003, for the treatment of ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome.

Company Information

Company

Drug Farm

Location

Shanghai, Shanghai, China

About

Drug Farm is a China- and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development. For more information please visit: www.drug-farm.com/

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Drug Farm's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.